What is the definitive treatment for a prosthetic joint infection presenting with a sinus tract?

Definitive Treatment for Prosthetic Joint Infection with Sinus Tract

The definitive treatment for prosthetic joint infection presenting with a sinus tract is two-stage exchange arthroplasty, as debridement and retention is contraindicated in the presence of a sinus tract due to significantly increased failure rates. 1

Why Sinus Tract Precludes Debridement and Retention

• Sinus tract is a major criterion for PJI diagnosis and represents an absolute contraindication to debridement and retention strategies. 1
• The IDSA guidelines explicitly state that debridement without prosthesis removal has an increased risk of treatment failure in patients with a sinus tract. 1
• Patients with sinus tracts have nearly 3-fold higher odds of treatment failure (OR = 2.94) compared to those without sinus tracts when attempting salvage procedures. 2
• The presence of a sinus tract serves as a proxy for poor periarticular soft tissue quality, compromised nutritional status, and often multiple prior operations—all factors that doom retention strategies. 2

Two-Stage Exchange Protocol

The two-stage exchange is the standard definitive treatment in the United States for chronic PJI with sinus tract, with an overall success rate of 87%. 1

First Stage: Resection Arthroplasty

• Remove all infected prosthetic components and cement completely. 1
• Perform extensive debridement of all infected periprosthetic tissue. 1
• Place antibiotic-impregnated cement spacers (static or articulating) to manage dead space and deliver local antimicrobial therapy. 1
• Important caveat: Some experts do not recommend spacers for MRSA infection, small-colony variants, or fungal infections, as spacers may be detrimental to infection eradication in these specific scenarios. 1

Interstage Period

• Administer systemic antimicrobial therapy for weeks to months. 1
• Be aware that 28% of patients experience complications during the interstage period at a median of 47 days, with 4% mortality risk during this phase. 3
• Obtain ESR and CRP prior to reimplantation to assess treatment success. 1
• The panel does not endorse routine synovial fluid examination and cultures before reimplantation in all patients, but this can be used selectively when persistent infection is suspected. 1

Second Stage: Reimplantation

• Reimplant new prosthesis weeks to months after resection, depending on prosthesis type and infection control. 1
• Both cemented and non-cemented prostheses can be utilized based on technical factors. 1
• FDA-approved aminoglycoside-containing cements are available for fixation at reimplantation. 1

Critical Clinical Pitfalls

Many patients with sinus tracts undergo inappropriate non-definitive procedures before receiving proper treatment, increasing overall morbidity. 4

• In one series, 44% of patients with documented sinus tracts underwent interventional radiology drain placement, local wound care, or irrigation and debridement before definitive two-stage exchange. 4
• These non-definitive procedures expose patients to inherent surgical risks without addressing the underlying infection. 4
• 78% of patients requiring two-stage revision present with sinus tracts, making this clinical sign a major characteristic that should immediately trigger definitive surgical planning. 5

Alternative Scenarios (Rare Exceptions)

One-stage exchange is not commonly performed in the United States but may be considered only in highly selected THA infections where: 1

• The pathogen identity is known preoperatively
• The organism is susceptible to oral antimicrobials with excellent bioavailability
• There is a good soft tissue envelope
• Bone grafting is not required
• This option is generally not appropriate for patients with sinus tracts given the poor soft tissue quality they represent

Permanent resection arthroplasty should be considered for: 1

• Non-ambulatory patients
• Limited bone stock or poor soft tissue coverage
• Highly resistant organisms with limited medical therapy options
• Medical conditions precluding multiple major surgeries
• Failed previous two-stage exchange with unacceptable recurrent infection risk

Success Rates and Realistic Expectations

• While two-stage exchange has an 87% reported success rate, only 56% of patients are successfully treated at one year when considering all complications. 3
• Of those successfully treated, 36% require no antibiotic suppression while 19% require chronic suppression. 3
• The 18% mortality rate at mean 3.7 years post-treatment underscores the significant morbidity of this condition. 3
• More than one two-stage exchange can be successful if the first fails, though this should be carefully considered. 1